Navigation Links
BioMS Medical provides corporate update
Date:12/17/2009

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 17 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS) today provided the following update on corporate developments:

    Dirucotide Update
    -----------------

The Company has completed its substantive review of the data from the discontinued late-stage trials for dirucotide, its drug candidate for the treatment of multiple sclerosis (MS). BioMS has decided that it will explore a compassionate access and research program with limited financial commitment, but that it will not pursue further late stage clinical trials with dirucotide in MS.

    Strategic Investment
    --------------------

BioMS earlier today announced a $12.0 million strategic investment in Spectral Diagnostics Inc., in exchange for approximately 48% of Spectral's issued and outstanding common shares, once the proposed transaction is completed. BioMS will also support Spectral and its management team in the development of its lead product, Toraymyxin(TM), in the US under a three-year $3 million contract to supply BioMS' management services to Spectral.

"Spectral represents the type of development opportunity that BioMS is seeking and ideally suited for: investment in a late-stage clinical program with a large market opportunity, and the ability to assist in the successful development of a project using our management expertise," said Kevin Giese, President and CEO of BioMS Medical. "BioMS will continue to leverage its resources and management team to pursue additional opportunities to realize shareholder value."

Spectral is a leader in the battle against sepsis. Spectral's Endotoxin Activity Assay (EAA(TM)) is the only FDA cleared assay for the measurement of endotoxin in the bloodstream. With the growing awareness for the role of endotoxemia in sepsis, the EAA(TM) can be used to identify patients, enable therapeutics and monitor treatment.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... March 26, 2015 ReliantHeart, Inc., an ... Transonic, a supplier of precision transit-time flow measurement solutions, ... greatly improve the efficiency of the HeartAssist5® ... patients to experience greater mobility and peace of mind. ... miniature flow board, will draw 1/6th of the power ...
(Date:3/26/2015)... March 26, 2015 WriteResult, a premier ... researchers from Yale University’s School of Public Health and ... participants during a 4 month-long project. The goal of ... low income families with free access to fresh produce ... diet-related health concerns like high blood pressure, diabetes and ...
(Date:3/25/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... recent discussions with certain shareholders representing approximately 45% of ... dealing with certain matters including the appointment of auditors ... March 26, 2015 (the "Meeting") it intends to adjourn ... take place when the Meeting reconvenes. The Meeting will ...
(Date:3/25/2015)... , March 25, 2015  S&P Capital ... Factual Stock Report coverage on Abattis Bioceuticals ... ATTBF; CSE: ATT): is a specialty biotechnology company ... cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, ... in North America . The ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 2Yale and New Haven Farms Improving Patient Health with WriteResult's myPROpad™ 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... BERNARDSVILLE, N.J., March 16 Protocol Driven Healthcare ... its health risk assessment (HRA), the ConXus(R) ... low literacy and reduces processing costs of paper assessments. ... adult HRA, but joins PDHI,s suite of ConXus ...
... Provider, Offers Traceability Down to the Unit Level to Secure ... ... Southborough, MA (PRWEB) March 16, 2009 -- PHARMORX ... technology services provider, today announced the availability of its new ...
... Application Includes Data from a Comparative Trial in ... Inc. announced today that its supplemental New Drug ... Drug Administration (FDA) seeking market approval of Durezol(TM) ... uveitis has been accepted for review. Durezol, ...
Cached Biology Technology:PDHI Launches Short Form of Its ConXus Profile Health Assessment 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 2PHARMORX Security Introduces New Technology Solutions for Counterfeiting, Grey Market Diversion, Track & Trace 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 2Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 3Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 4Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA 5
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
(Date:3/12/2015)... Va. , March 12, 2015 IriTech, ... and a member of the Texas Instruments Design Network, ... Naidu has demonstrated its IriShield USB MK2120U device ... scanning facility for pension distribution. The ... assembled to be marketed in India ...
(Date:3/11/2015)... DUBLIN , Mar. 11, 2015 Research and ... addition of the "Access Control Market by Product, ... to 2020" report to their offering. , ... is expected to reach $10.4 billion by 2020, with ... control market report covers the products types such as ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 2Indian States See IriTech's Scanner Bolstering Efficiency of Authentication for Aadhaar 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... from the University of California at San Francisco (UCSF) ... dedicated to the brain that the controversy is over: ... dead. , The cerebral cortex is a sheet of ... that process particular aspects of sensation, movement and cognition. ...
... of genes has shed light on the role of gene ... in Proceedings of the National Academy of Sciences USA, was ... , Dr Robert Beiko, Professor Mark Ragan and Mr ... in an effort to map how genes are shared between ...
... used by the U.S. military to track vehicle convoys in ... little-known world of pygmy elephants in Borneo. , ... elephant's being captured and outfitted with a collar that can ... the first time, the public can track the movements of ...
Cached Biology News:MIT researcher presents new view of how the cortex forms 2Lateral thinking produces first map of gene transmission 2WWF peeks into mysterious life of Borneo's pygmy elephants 2
... System brings together two mature, well-understood ... capture surfaces. This combination produces a ... the detection of molecular binding events ... , Protein-specific capture molecules are immobilized ...
... polymers) are prepared by ... the enzyme, polynucleotide phosphorylase, ... the appropriate, ribonucleoside diphosphate ... exception of catalog number ...
... comprehensive experiment based analysis package designed with ... sophisticated and powerful functionality., Image acquisition interface ... for easy image capture. Sequential and ... Playback Saturation Warning ...
...
Biology Products: